Geneoscopy is a molecular diagnostics company that develops non-invasive tests for the early detection of diseases such as colorectal cancer. The company leverages genomic technology to analyze patient samples, aiming to improve screening compliance and patient outcomes.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions. 

Missouri Technology Corporation

Dorm Room Fund

NT Asset

Cultivation Capital

Lightchain

Rodger Riney

BioGenerator

Innovatus Capital Partners

NT Investments

LabCorp

Morningside Venture Investments

Morningside Ventures

Geneoscopy

COM:GENEOSCOPY

Geneoscopy

Analysis Not Available